Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Rev Gastroenterol Mex ; 77(3): 114-8, 2012.
Artigo em Espanhol | MEDLINE | ID: mdl-22921101

RESUMO

BACKGROUND: In Mexico, the prevalence of Helicobacter pylori (H. pylori) infection is high. The bacterial eradication rate with the administration of antibiotic regimens recommended by international guidelines is not yet clear. AIMS: To determine the eradication frequency of H. pylori infection in the adult Mexican population that underwent treatment with the conventional triple regimen. MATERIAL AND METHODS: A cross-sectional study was carried out that evaluated the effectiveness of the triple regimen in individuals with confirmed infection that received consensual treatment and then underwent tests to corroborate eradication. RESULTS: From a total of 249 potential case records, 26 did not meet the inclusion criteria. Two hundred and twenty-three patients were enrolled for analysis, 64,00% women and 36,00% men, with a mean age of 49,4 years (range 17-86). Comorbidities presented in 55,60% of the patients and 28,60% referred to chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs). Bacterial eradication with the triple regimen was 65,50% (146/223); of the 77 patients with no eradication, 11 received a quadruple regimen as second-line treatment resulting in bacterial eradication in 5/11 (45,45%) patients, for an overall eradication of 67,70%. CONCLUSIONS: The eradication rate in our study population was suboptimal due to the probability of multiple factors that are difficult to identify, given the retrospective design of the study. A prospective and controlled evaluation of the recommended regimens needs to be carried out in order to determine their true effectiveness.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Estudos Transversais , Feminino , Infecções por Helicobacter/microbiologia , Humanos , Masculino , México , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
2.
Rev Gastroenterol Mex ; 73(4): 242-6, 2008.
Artigo em Espanhol | MEDLINE | ID: mdl-19666275

RESUMO

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology, probably immune-mediated. PSC is frequently associated with Inflammatory Bowel Disease, usually Ulcerative Colitis and less commonly with Crohn's disease. The small-duct PSC variant occurs in 5%of patients. Eosinophilic gastroenteritis (EG) is another chronic inflammatory disease, characterized by eosinophilic infiltration limited to the digestive tract, and probably of immunoallergic origin. EG is frequently observed in children but it's less commonly seen in adults. EG can affect any segment of the gastrointestinal tract, and recently it has been described an increase in the incidence of the esophagic variant, termed eosinophilic esophagitis.Ileocolonic involvement in EG is rare and clinical manifestations depend of the intestinal layer affected. Patients with mucosal infiltration complain of abdominal pain, fecal occult blood loss and/or protein-losing enteropaty, while signs and symptoms of obstruction are common in those with muscular EG, finally involvement of the serosal layer occurs in 10% and typically presents as eosinophil-rich ascitis. Response to steroids usually is excellent. There is a previous publication in the literature documenting the association of PSC and EG. Here we describe the first case of small-duct PSC associated to EG with ileocolonic involvement.


Assuntos
Colangite Esclerosante/patologia , Gastroenterite/patologia , Adulto , Ductos Biliares/patologia , Colangite Esclerosante/diagnóstico por imagem , Colangite Esclerosante/etiologia , Colo Sigmoide/patologia , Enterocolite/patologia , Gastroenterite/diagnóstico por imagem , Gastroenterite/etiologia , Humanos , Mucosa Intestinal/patologia , Intestinos/diagnóstico por imagem , Imageamento por Ressonância Magnética , Masculino , Radiografia
3.
J Leukoc Biol ; 65(5): 641-8, 1999 May.
Artigo em Inglês | MEDLINE | ID: mdl-10331493

RESUMO

According to CD28 molecule expression, CD8+ T cells can be classed as CD28bright, CD28dim, and CD28-. The CD28dim T cells were found to derive from mitogenic stimulated CD28-T cells but also from CD28bright T cells through a mechanism of CD28 down-modulation. Moreover, after prolonged in vitro interleukin-2 stimulation, clonal CD28bright, cells showed a CD28dim expression before further evolution to a stable CD28-phenotype. This loss was concomitant with the disappearance of CD28 mRNA. A study of the cytokine production pattern revealed that CD28dim and CD28- T cell clones produced similar levels of type 1 and type 2 cytokines, which differed from those produced by the CD28bright T cell clones. A high percentage of CD28dim and CD28- cells, with similarities in their cytokine production pattern, were found in the blood samples of HIV-infected patients, as compared to healthy donors. The CD28 down-modulation may account for the increased number of CD8+CD28- T cells in HIV-infected patients.


Assuntos
Antígenos CD28/biossíntese , Linfócitos T CD8-Positivos/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Ativação Linfocitária/imunologia , Subpopulações de Linfócitos T/imunologia , Adulto , Antígenos CD28/imunologia , Linfócitos T CD8-Positivos/metabolismo , Células Clonais , Feminino , Humanos , Imunofenotipagem , Interferon gama/metabolismo , Interleucinas/metabolismo , Masculino , Subpopulações de Linfócitos T/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA